Oppenheimer says it continues to view GW Pharmaceuticals favorably (GWPH -6.3%) even after yesterday’s profit miss.
“Following a year of solid commercial execution in
2019, we expect 2020 momentum from both commercial execution and
clinical/regulatory catalysts,” reads the firm’s update.
Oppenheimer sees key catalysts this year including
a FDA decision regarding Epidiolex label expansion in tuberous
sclerosis complex and Epidyolex European Union launch updates. Epidyolex
EU-5 pricing and reimbursement updates and initial data from CBDV open
label study in autism in 2020 could also spark shares.
Oppenheimer keeps an Outperform rating and price target of $173 in place.
https://seekingalpha.com/news/3545852-oppenheimer-defends-gw-pharmaceuticals
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.